Filtered By:
Cancer: Acute Leukemia
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 260 results found since Jan 2013.
Knockdown of neurotrophin receptor-interacting melanoma-associated antigen homolog inhibits acute myeloid leukemia cell growth via the ERK pathway
In this study, NRAGE was identified as a tumor promoter in AML, which had an effect on cell proliferation, cell survival, and cell cycle through the ERK signaling pathway in AML cells.PMID:37635487 | DOI:10.4103/cjop.CJOP-D-22-00162
Source: The Chinese Journal of Physiology - August 28, 2023 Category: Physiology Authors: Hongxia Zhang Guangsheng Wu Beili Chen Source Type: research
Effect of siRNA-mediated silencing of p53R2 gene on sensitivity of T-ALL cellsto Daunorubicin
CONCLUSION: The results of the present study showed that silencing of p53R2 using siRNA can significantly increase the antitumor effects of Daunorubicin on T-ALL cells. Therefore, p53R2 siRNA has the potential to be used as an adjuvant therapy in combination with Daunorubicin in T-ALL.PMID:37419428 | DOI:10.1016/j.gene.2023.147622
Source: Gene - July 7, 2023 Category: Genetics & Stem Cells Authors: Omid KianiGhalesardi Farhad Zaker Abbas Ghotaslou Hassan Boustani Mohammad Reza Rezvani Jafar Kiani Minoo Shahidi Source Type: research
Cancers, Vol. 15, Pages 3432: Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1
In this study, using chromatin immunoprecipitation (ChIP) assay and siRNA, we demonstrate that vitamin D/VDR regulates PD-L1 expression in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells. We have examined whether a VDR antagonist, MeTC7, can inhibit PD-L1. To ensure that MeTC7 inhibits VDR/PD-L1 without off-target effects, we examined competitive inhibition of VDR by MeTC7, utilizing ligand-dependent dimerization of VDR-RXR, RXR-RXR, and VDR-coactivators in a mammalian 2-hybrid (M2H) assay. MeTC7 inhibits VDR selectively, suppresses PD-L1 expression sparing PD-L2, and inhibits the cell viability, clon...
Source: Cancers - June 30, 2023 Category: Cancer & Oncology Authors: Negar Khazan Emily R. Quarato Niloy A. Singh Cameron W. A. Snyder Taylor Moore John P. Miller Masato Yasui Yuki Teramoto Takuro Goto Sabeeha Reshi Jennifer Hong Naixin Zhang Diya Pandey Priyanka Srivastava Alexandra Morell Hiroki Kawano Yuko Kawano Thomas Tags: Article Source Type: research
Combined inhibition of XIAP and autophagy induces apoptosis and differentiation in acute myeloid leukaemia
J Cell Mol Med. 2023 May 8. doi: 10.1111/jcmm.17765. Online ahead of print.ABSTRACTPerturbations in autophagy, apoptosis and differentiation have greatly affected the progression and therapy of acute myeloid leukaemia (AML). The role of X-linked inhibitor of apoptosis (XIAP)-related autophagy remains unclear in AML therapeutics. Here, we found that XIAP was highly expressed and associated with poor overall survival in patients with AML. Furthermore, pharmacologic inhibition of XIAP using birinapant or XIAP knockdown via siRNA impaired the proliferation and clonogenic capacity by inducing autophagy and apoptosis in AML cell...
Source: J Cell Mol Med - May 8, 2023 Category: Molecular Biology Authors: Ziyang Huang Jifan Zhou Yinyan Jiang Yixiang Han Xiaofang Wang Fanfan Li Songfu Jiang Kang Yu Shenghui Zhang Source Type: research
SPHINX-Based Combination Therapy as a Potential Novel Treatment Strategy for Acute Myeloid Leukaemia
Conclusion: We suggest that specific types of leukaemia may present an opportunity for the development of SRPK1-targeted therapies to be used in combination with established chemotherapeutic drugs.PMID:36895328 | PMC:PMC9988938 | DOI:10.3389/bjbs.2023.11041
Source: British Journal of Biomedical Science - March 10, 2023 Category: Laboratory Medicine Authors: Chigeru Wodi Tareg Belali Ruth Morse Sean Porazinski Michael Ladomery Source Type: research
